Respiratory viral infections, typically mild in healthy populations, pose significant threats to immunocompromised patients. This editorial examines infections caused by respiratory syncytial virus (RSV), parainfluenza, influenza, and adenovirus in vulnerable populations including bone marrow and lung transplant recipients, and patients on myeloablative chemotherapy. Approximately 5% of bone marrow transplant patients develop serious respiratory virus infections, with 60-80% progressing to pneumonia and mortality rates of 10-40% overall, reaching 80% for RSV cases. Upper respiratory symptoms typically precede lower respiratory tract involvement by 5-6 days. Key viruses differ in pathogenesis: RSV causes primary viral pneumonitis, influenza may lead to secondary bacterial pneumonia, and adenovirus causes disseminated systemic infection. Diagnosis relies on immunofluorescence and culture from throat swabs, nasopharyngeal aspirates, or bronchoalveolar lavage. Treatment options include ribavirin for RSV and antivirals like amantadine for influenza, though controlled trial data remain limited. Prevention strategies emphasize infection control measures, patient isolation, and pre-transplant vaccination. The authors highlight critical gaps in prospective epidemiological data and the urgent need for controlled clinical trials to establish antiviral efficacy in immunocompromised populations.

Key findings

• Up to 5% of bone marrow transplant patients develop serious respiratory virus infections with 60-80% progressing to pneumonia and mortality rates up to 80% for RSV
• RSV causes primary viral pneumonitis while influenza may cause secondary bacterial pneumonia and adenovirus causes disseminated systemic infection
• Immunofluorescence and culture from bronchoalveolar lavage are preferred diagnostic methods, with rapid diagnosis essential for guiding acute management
• Ribavirin shows promise for RSV treatment when given early, and pre-emptive therapy should be considered when upper respiratory symptoms appear
• Prospective longitudinal studies and controlled clinical trials of antiviral agents are critically needed to establish true prevalence and treatment efficacy